GSK, Sanofi begin new COVID-19 vaccine tried after setback last year

Must Read

Ryan Hodge : “Today anyone can become a social media celebrity”

In conversation with one of the top celebrity social media managers in the UK, Ryan Hodge who has amassed...

Sharoz Dawa Shares Tips To Run Google Ads

Sharoz Dawa is an enlightening influencer who operates one of the largest and most believed education portals in India....

Do You Need Offshore Accident Lawyer?

Ship and rig owners and operators have a responsibility to supply crew members with the best atmosphere that is...

Britain’s GSK and France’s Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate and aim to reach the final testing stage in the second quarter.

If the results are conclusive, the two drug makers hope to see the vaccine approved by the fourth quarter after having initially targeted the first half of this year.

The move comes after the drug makers in December said their vaccine would be delayed after clinical trials showed an insufficient immune response in older people.

The new trial will aim at evaluating the safety, tolerability, and immune response of the vaccine in 720 healthy adults across the United States, Honduras, and Panama, the companies said.

Sanofi and GSK’s candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

The study will test two injections given 21 days apart.

 

 

Latest News

Shetland Season 6: Release Date, Plot, Cast And More.

Even though the show is renewed by BBC One, fans have to wait a little longer to see "Shetland...
- Advertisement -